Literature DB >> 7752196

Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.

K A Jacobson1, S M Siddiqi, M E Olah, X D Ji, N Melman, K Bellamkonda, Y Meshulam, G L Stiles, H O Kim.   

Abstract

9-Alkyladenine derivatives and ribose-modified N6-benzyladenosine derivatives were synthesized in an effort to identify selective ligands for the rat A3 adenosine receptor and leads for the development of antagonists. The derivatives contained structural features previously determined to be important for A3 selectivity in adenosine derivatives, such as an N6-(3-iodobenzyl) moiety, and were further substituted at the 2-position with halo, amino, or thio groups. Affinity was determined in radioligand binding assays at rat brain A3 receptors stably expressed in Chinese hamster ovary (CHO) cells, using [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide)), and at rat brain A1 and A2a receptors using [3H]-N6-PIA ((R)-N6-phenylisopropyladenosine) and [3H]CGS 21680 (2-[[[4-(2-carboxyethyl)-phenyl]ethyl]amino]-5'- (N-ethylcarbamoyl)adenosine), respectively. A series of N6-(3-iodobenzyl) 2-amino derivatives indicated that a small 2-alkylamino group, e.g., methylamino, was favored at A3 receptors. N6-(3-Iodobenzyl)-9-methyl-2-(methylthio)adenine was 61-fold more potent than the corresponding 2-methoxy ether at A3 receptors and of comparable affinity at A1 and A2a receptors, resulting in a 3-6-fold selectivity for A3 receptors. A pair of chiral N6-(3-iodobenzyl) 9-(2,3-dihydroxypropyl) derivatives showed stereoselectivity, with the R-enantiomer favored at A3 receptors by 5.7-fold. 2-Chloro-9-(beta-D-erythrofuranosyl)-N6-(3-iodobenzyl)adenine had a Ki value at A3 receptors of 0.28 microM. 2-Chloro-9-[2-amino-2,3-dideoxy-beta-D-5-(methylcarbamoyl)- arabinofuranosyl]-N6-(3-iodobenzyl)adenine was moderately selective for A1 and A3 vs A2a receptors. A 3'-deoxy analogue of a highly A3-selective adenosine derivative retained selectivity in binding and was a full agonist in the inhibition of adenylyl cyclase mediated via cloned rat A3 receptors expressed in CHO cells. The 3'-OH and 4'-CH2OH groups of adenosine are not required for activation at A3 receptors. A number of 2',3'-dideoxyadenosines and 9-acyclic-substituted adenines appear to inhibit adenylyl cyclase at the allosteric "P" site.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752196      PMCID: PMC3445626          DOI: 10.1021/jm00010a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

1.  Reversal of synaptic depression by serotonin at Aplysia sensory neuron synapses involves activation of adenylyl cyclase.

Authors:  B A Goldsmith; T W Abrams
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

2.  Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts.

Authors:  R F Bruns
Journal:  Biochem Pharmacol       Date:  1981-02-15       Impact factor: 5.858

3.  Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine.

Authors:  U Schwabe; T Trost
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-09       Impact factor: 3.000

4.  Ribose-modified adenosine analogues as adenosine receptor agonists.

Authors:  M D Taylor; W H Moos; H W Hamilton; D S Szotek; W C Patt; E W Badger; J A Bristol; R F Bruns; T G Heffner; T E Mertz
Journal:  J Med Chem       Date:  1986-03       Impact factor: 7.446

5.  [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.

Authors:  M F Jarvis; R Schulz; A J Hutchison; U H Do; M A Sills; M Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

6.  5'-Deoxy-5'-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types.

Authors:  R Munshi; A S Clanachan; H P Baer
Journal:  Biochem Pharmacol       Date:  1988-05-15       Impact factor: 5.858

7.  N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists.

Authors:  D Ukena; W L Padgett; O Hong; J W Daly; D T Daly; R A Olsson
Journal:  FEBS Lett       Date:  1987-05-11       Impact factor: 4.124

8.  N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.

Authors:  R D Thompson; S Secunda; J W Daly; R A Olsson
Journal:  J Med Chem       Date:  1991-09       Impact factor: 7.446

9.  2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors.

Authors:  M J Lohse; K N Klotz; E Diekmann; K Friedrich; U Schwabe
Journal:  Eur J Pharmacol       Date:  1988-10-26       Impact factor: 4.432

10.  2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.

Authors:  H O Kim; X D Ji; S M Siddiqi; M E Olah; G L Stiles; K A Jacobson
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

View more
  19 in total

1.  Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells.

Authors:  B C Suh; T D Kim; J U Lee; J K Seong; K T Kim
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

2.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

3.  Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.

Authors:  Philippe Van Rompaey; Kenneth A Jacobson; Ariel S Gross; Zhan-Guo Gao; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

Review 4.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions.

Authors:  Dilip K Tosh; Silvia Paoletta; Khai Phan; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2012-06-11       Impact factor: 4.345

6.  CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS.

Authors:  Maria Rosito; Cristina Deflorio; Cristina Limatola; Flavia Trettel
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

7.  Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element.

Authors:  Dilip K Tosh; Khai Phan; Francesca Deflorian; Qiang Wei; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2011-08-11       Impact factor: 4.345

Review 8.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

9.  Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.

Authors:  Lak Shin Jeong; Shantanu Pal; Seung Ah Choe; Won Jun Choi; Kenneth A Jacobson; Zhan-Guo Gao; Athena M Klutz; Xiyan Hou; Hea Ok Kim; Hyuk Woo Lee; Sang Kook Lee; Dilip K Tosh; Hyung Ryong Moon
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Activation and Desensitization of Rat A3-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides.

Authors:  Kyung-Sun Park; Carsten Hoffmann; Hea Ok Kim; William L Padgett; John W Daly; Roberta Brambilla; Cristina Motta; Maria P Abbracchio; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1998-06-01       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.